

Johan W De Fijter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8653752/publications.pdf>

Version: 2024-02-01

114
papers

4,372
citations

109321

35
h-index

123424

61
g-index

114
all docs

114
docs citations

114
times ranked

5914
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiplex LC-MS/MS Testing for Early Detection of Kidney Injury: A Next-Generation Alternative to Conventional Immunoassays?. <i>Journal of Applied Laboratory Medicine</i> , The, 2022, 7, 923-930.	1.3	3
2	Implementation of molecular matching in transplantation requires further characterization of both immunogenicity and antigenicity of individual HLA epitopes. <i>Human Immunology</i> , 2022, 83, 256-263.	2.4	14
3	Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 191-203.	3.5	7
4	Rational selection of a biomarker panel targeting unmet clinical needs in kidney injury. <i>Clinical Proteomics</i> , 2021, 18, 10.	2.1	14
5	Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal: The randomized prospective, single-center, open-label TRITON study. <i>American Journal of Transplantation</i> , 2021, 21, 3055-3065.	4.7	25
6	Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1201-1215.	3.5	5
7	Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation. <i>Drug Discovery Today</i> , 2021, 26, 2527-2546.	6.4	12
8	Single antigen testing to reduce early antibody-mediated rejection risk in female recipients of a spousal donor kidney. <i>Transplant Immunology</i> , 2021, 67, 101407.	1.2	0
9	Serum Potassium and Mortality Risk in Hemodialysis Patients: A Cohort Study. <i>Kidney Medicine</i> , 2021, 4, 100379.	2.0	10
10	Development and Provisional Validation of a Multiplex LC-MRM-MS Test for Timely Kidney Injury Detection in Urine. <i>Journal of Proteome Research</i> , 2021, 20, 5304-5314.	3.7	13
11	T-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 784040.	4.8	8
12	HLA-DQ-Specific Recombinant Human Monoclonal Antibodies Allow for In-Depth Analysis of HLA-DQ Epitopes. <i>Frontiers in Immunology</i> , 2021, 12, 761893.	4.8	8
13	A Comprehensive Evaluation of the Antibody-Verified Status of Eplets Listed in the HLA Epitope Registry. <i>Frontiers in Immunology</i> , 2021, 12, 800946.	4.8	18
14	Cardiovascular Effects of Autologous Bone Marrow-Derived Mesenchymal Stromal Cell Therapy With Early Tacrolimus Withdrawal in Renal Transplant Recipients: An Analysis of the Randomized TRITON Study. <i>Journal of the American Heart Association</i> , 2021, 10, e023300.	3.7	3
15	Dietary protein intake and kidney function decline after myocardial infarction: the Alpha Omega Cohort. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 106-115.	0.7	38
16	Medication non-adherence after kidney transplantation: A critical appraisal and systematic review. <i>Transplantation Reviews</i> , 2020, 34, 100511.	2.9	61
17	No Apparent Influence of Nonadherence on Tacrolimus Inpatient Variability in Stable Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 702-709.	2.0	8
18	Circulating Long Noncoding RNA LNC-EPHA6 Associates with Acute Rejection after Kidney Transplantation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5616.	4.1	8

#	ARTICLE	IF	CITATIONS
19	Skin disorders indicating peripheral arterial occlusive disease and chronic venous insufficiency in organ transplant recipients. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107623.	2.3	1
20	Biopsy-Controlled Non-Invasive Quantification of Collagen Type VI in Kidney Transplant Recipients: A Post-Hoc Analysis of the MECANO Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3216.	2.4	7
21	Diabetic nephropathy alters circulating long noncoding RNA levels that normalize following simultaneous pancreas-kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 3451-3461.	4.7	10
22	Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2666-2669.	3.0	2
23	Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2020, 98, 989-998.	5.2	36
24	Superior Long-term Survival for Simultaneous Pancreas-Kidney Transplantation as Renal Replacement Therapy: 30-Year Follow-up of a Nationwide Cohort. <i>Diabetes Care</i> , 2020, 43, 321-328.	8.6	42
25	Transplanting the Elderly: Mandatory Age- and Minimal Histocompatibility Matching. <i>Frontiers in Immunology</i> , 2020, 11, 359.	4.8	18
26	Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics. <i>American Journal of Transplantation</i> , 2020, 20, 1896-1901.	4.7	51
27	Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study. <i>American Journal of Transplantation</i> , 2020, 20, 2905-2915.	4.7	34
28	Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease. <i>PLoS ONE</i> , 2020, 15, e0233213.	2.5	16
29	Urinary metabolites predict prolonged duration of delayed graft function in DCD kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 110-122.	4.7	15
30	Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. <i>Gastroenterology</i> , 2019, 157, 481-491.e7.	1.3	42
31	Low Birth Weight and Kidney Function in Middle-Aged Men and Women: The Netherlands Epidemiology of Obesity Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 751-760.	1.9	12
32	USE OF THIAZIDE DIURETICS DOES NOT WORSEN DISEASE PROGRESSION IN ADPKD. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
33	URINARY ALANINE/CITRATE RATIO ASSOCIATES WITH THE RATE OF EGFR DECLINE IN PATIENTS WITH ADPKD. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
34	Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. <i>Scientific Reports</i> , 2019, 9, 16632.	3.3	35
35	Early remote ischaemic preconditioning leads to sustained improvement in allograft function after live donor kidney transplantation: long-term outcomes in the REal Protection Against Ischaemia-Reperfusion in transplantation (REPAIR) randomised trial. <i>British Journal of Anaesthesia</i> , 2019, 123, 584-591.	3.4	19
36	Kidney injury biomarkers in an academic hospital setting: where are we now?. , 2019, 40, 79-97.		16

#	ARTICLE	IF	CITATIONS
37	Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients. <i>American Journal of Transplantation</i> , 2019, 19, 2926-2933.	4.7	32
38	Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients. <i>Kidney International Reports</i> , 2019, 4, 833-841.	0.8	3
39	Antibodies against ARHGDI3 are associated with long-term kidney graft loss. <i>American Journal of Transplantation</i> , 2019, 19, 3335-3344.	4.7	46
40	Source and Relevance of the BK Polyomavirus Genotype for Infection After Kidney Transplantation. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz078.	0.9	17
41	Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis. <i>Modern Pathology</i> , 2019, 32, 1147-1157.	5.5	43
42	Presence of intragraft B cells during acute renal allograft rejection is accompanied by changes in peripheral blood B cell subsets. <i>Clinical and Experimental Immunology</i> , 2019, 196, 403-414.	2.6	10
43	HLA-B51 Reduces Risk of BK Polyomavirus Viremia After Kidney Transplantation. <i>Transplantation</i> , 2019, 103, e386-e387.	1.0	0
44	Reduced Risk of BK Polyomavirus Infection in HLA-B51 positive Kidney Transplant Recipients. <i>Transplantation</i> , 2019, 103, 604-612.	1.0	25
45	Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival. <i>Transplantation</i> , 2019, 103, 789-797.	1.0	31
46	Urinary TIMP-2 Predicts the Presence and Duration of Delayed Graft Function in Donation After Circulatory Death Kidney Transplant Recipients. <i>Transplantation</i> , 2019, 103, 1014-1023.	1.0	23
47	Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1417-1422.	0.7	7
48	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 601-615.	2.4	56
49	A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1056-1063.	0.7	17
50	Retrospective study on detection, treatment, and clinical outcome of graft thrombosis following pancreas transplantation. <i>Transplant International</i> , 2019, 32, 410-417.	1.6	20
51	Elevated intragraft expression of innate immunity and cell death-related markers is a risk factor for adverse graft outcome. <i>Transplant Immunology</i> , 2018, 48, 39-46.	1.2	5
52	Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant. <i>American Journal of Transplantation</i> , 2018, 18, 2274-2284.	4.7	65
53	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling) <i>Trends in Microbiology</i> , 2018, 26, 101-111.	0.7	11
54	A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1575-1586.	2.4	12

#	ARTICLE	IF	CITATIONS
55	Local delivery of liposomal prednisolone leads to an anti-inflammatory profile in renal ischaemiaâ€“reperfusion injury in the rat. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 44-53.	0.7	26
56	Mesenchymal Stromal Cell Therapy for Solid Organ Transplantation. <i>Transplantation</i> , 2018, 102, 35-43.	1.0	47
57	Pancreas Transplantation With Grafts From Donors Deceased After Circulatory Death. <i>Transplantation</i> , 2018, 102, 333-339.	1.0	27
58	Body-fat indicators and kidney function decline in older post-myocardial infarction patients: The Alpha Omega Cohort Study. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 90-99.	1.8	9
59	Early Steroid Withdrawal Compared With Standard Immunosuppression in Kidney Transplantation - Interim Analysis of the Amsterdam-Leiden-Groningen Randomized Controlled Trial. <i>Transplantation Direct</i> , 2018, 4, e354.	1.6	9
60	Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients. <i>Frontiers in Immunology</i> , 2018, 9, 3002.	4.8	25
61	Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2010.	7.4	78
62	Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2889-2902.	2.4	70
63	PIRCHE-II Is Related to Graft Failure after Kidney Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 321.	4.8	63
64	Cardiovascular Risk Factors Accelerate Kidney Function Decline in Postâ€“Myocardial Infarctionâ€“Patients: The Alpha Omega Cohort Study. <i>Kidney International Reports</i> , 2018, 3, 879-888.	0.8	10
65	Pretransplantation Donorâ€“Recipient Pair Seroreactivity Against BK Polyomavirus Predicts Viremia and Nephropathy After Kidney Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 161-172.	4.7	58
66	Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. <i>Drug Safety</i> , 2017, 40, 153-167.	3.2	16
67	Incidence and outcome of BK polyomavirus infection in a multicenter randomized controlled trial with renal transplant patients receiving cyclosporineâ€“, mycophenolate sodiumâ€“, or everolimusâ€“based lowâ€“dose immunosuppressive therapy. <i>Transplant Infectious Disease</i> , 2017, 19, e12687.	1.7	15
68	Cancer and mTOR Inhibitors in Transplant Recipients. <i>Transplantation</i> , 2017, 101, 45-55.	1.0	104
69	Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2017, 389, 2117-2127.	13.7	278
70	Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. <i>American Journal of Transplantation</i> , 2017, 17, 1853-1867.	4.7	68
71	Kidney injury molecule-1 staining in renal allograft biopsies 10 days after transplantation is inversely correlated with functioning proximal tubular epithelial cells. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 2132-2141.	0.7	18
72	Acute Rejection After Kidney Transplantation Associates With Circulating MicroRNAs and Vascular Injury. <i>Transplantation Direct</i> , 2017, 3, e174.	1.6	25

#	ARTICLE	IF	CITATIONS
73	Recurrence of glomerulonephritis: an underestimated and unmet medical need. <i>Kidney International</i> , 2017, 92, 294-296.	5.2	4
74	Stretching the Limits of Renal Transplantation in Elderly Recipients of Grafts from Elderly Deceased Donors. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 621-631.	6.1	63
75	Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial. <i>American Journal of Transplantation</i> , 2017, 17, 1020-1030.	4.7	29
76	Epidemiology and management of hypertension in paediatric and young adult kidney transplant recipients in The Netherlands. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 402-402.	0.7	3
77	Beneficial Immune Effects of Myeloid-Related Proteins in Kidney Transplant Rejection. <i>American Journal of Transplantation</i> , 2016, 16, 1441-1455.	4.7	20
78	Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. <i>American Journal of Transplantation</i> , 2016, 16, 246-253.	4.7	33
79	Mechanisms and risk assessment of steroid resistance in acute kidney transplant rejection. <i>Transplant Immunology</i> , 2016, 38, 3-14.	1.2	16
80	How can we reduce costs of solid-phase multiplex bead assays used to determine anti-HLA antibodies?. <i>Hla</i> , 2016, 88, 110-119.	0.6	15
81	Epidemiology and management of hypertension in paediatric and young adult kidney transplant recipients in The Netherlands. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1947-1956.	0.7	15
82	High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1515-1522.	0.7	14
83	Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 227-237.	2.4	11
84	The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1002-1013.	0.7	46
85	Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study. <i>Journal of Translational Medicine</i> , 2015, 13, 344.	4.4	59
86	Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients. <i>Journal of Immunology Research</i> , 2015, 2015, 1-14.	2.2	12
87	Circulating MicroRNAs Associate With Diabetic Nephropathy and Systemic Microvascular Damage and Normalize After Simultaneous Pancreas-Kidney Transplantation. <i>American Journal of Transplantation</i> , 2015, 15, 1081-1090.	4.7	73
88	Sirolimus and everolimus in kidney transplantation. <i>Drug Discovery Today</i> , 2015, 20, 1243-1249.	6.4	101
89	Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2239-2247.	6.1	97
90	Transplanting the elderly: Balancing aging with histocompatibility. <i>Transplantation Reviews</i> , 2015, 29, 205-211.	2.9	25

#	ARTICLE	IF	CITATIONS
91	Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2015, 66, 792-801.	1.9	36
92	Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-12.	2.5	69
93	Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients. Journal of Translational Medicine, 2014, 12, 331.	4.4	41
94	The Authors Reply:. Kidney International, 2014, 85, 713-714.	5.2	1
95	The PROCARE consortium: Toward an improved allocation strategy for kidney allografts. Transplant Immunology, 2014, 31, 184-190.	1.2	25
96	Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 2014, 63, 446-455.	1.9	59
97	Microvascular Damage in Type 1 Diabetic Patients Is Reversed in the First Year After Simultaneous Pancreas-Kidney Transplantation. American Journal of Transplantation, 2013, 13, 1272-1281.	4.7	46
98	Autologous Bone Marrow-Derived Mesenchymal Stromal Cells for the Treatment of Allograft Rejection After Renal Transplantation: Results of a Phase I Study. Stem Cells Translational Medicine, 2013, 2, 107-111.	3.3	277
99	Reply to O.R. Colegio et al. Journal of Clinical Oncology, 2013, 31, 3298-3298.	1.6	21
100	Tacrolimus Dosing in Mycophenolate-Treated Patients—Can We Get Away With Less?. Transplantation, 2011, 92, 10-11.	1.0	0
101	Counselling the elderly between hope and reality. Nephrology Dialysis Transplantation, 2011, 26, 2079-2081.	0.7	6
102	A case of mononucleosis infectiosa presenting with cholemic nephrosis. CKJ: Clinical Kidney Journal, 2011, 4, 170-172.	2.9	12
103	Rejection and function and chronic allograft dysfunction. Kidney International, 2010, 78, S38-S41.	5.2	44
104	Early Renal Ischemia-Reperfusion Injury in Humans Is Dominated by IL-6 Release from the Allograft. American Journal of Transplantation, 2009, 9, 1574-1584.	4.7	58
105	An old virtue to improve senior programs. Transplant International, 2009, 22, 259-268.	1.6	36
106	Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2009, 31, 187-197.	2.0	119
107	Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrology Dialysis Transplantation, 2007, 22, i23-i26.	0.7	54
108	The Impact of Age on Rejection in Kidney Transplantation. Drugs and Aging, 2005, 22, 433-449.	2.7	61

#	ARTICLE	IF	CITATIONS
109	Similar Reduction of Cytomegalovirus DNA Load by Oral Valganciclovir and Intravenous Ganciclovir on Pre-Emptive Therapy after Renal and Renal-Pancreas Transplantation. <i>Antiviral Therapy</i> , 2005, 10, 119-123.	1.0	21
110	Diabetic nephropathy and beta-cell replacement therapy. <i>Netherlands Journal of Medicine</i> , 2004, 62, 71-5.	0.5	0
111	Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. <i>Blood</i> , 2001, 98, 174-180.	1.4	156
112	Increased Immunogenicity and Cause of Graft Loss of Old Donor Kidneys. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1538-1546.	6.1	221
113	The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. <i>European Journal of Immunology</i> , 2000, 30, 1807-1812.	2.9	242
114	Increased IL-10 production by stimulated whole blood cultures in primary IgA nephropathy. <i>Clinical and Experimental Immunology</i> , 1998, 111, 429-434.	2.6	20